Legal Settlements, Stock Price Updates, Financial Results, and Commencement of Clinical Studies - Research Report on Johnson &

Legal Settlements, Stock Price Updates, Financial Results, and Commencement of
Clinical Studies - Research Report on Johnson & Johnson, Elan, Tenet, Opko and
                           Keryx Biopharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 7, 2013

NEW YORK, November 7, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Elan Corporation, plc (ADR) (NYSE: ELN), Tenet Healthcare
Corp. (NYSE: THC), Opko Health Inc. (NYSE: OPK), and Keryx Biopharmaceuticals
(NASDAQ: KERX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On November 4, 2013, Johnson & Johnson (Johnson & Johnson) and its two
subsidiaries, Janssen Pharmaceuticals, Inc. (Janssen) and Scios, Inc. (Scios)
jointly announced that they have finalized previously disclosed settlement
agreements with the U.S. Department of Justice (DOJ) and 45 states resolving
federal investigations and state Medicaid claims related to past promotional
practices of RISPERDAL from 1999 through 2005, and other matters. The Company
said that as a part of the resolution, Janssen will plead guilty to a single
misdemeanor violation of the Food, Drug, and Cosmetic Act for past promotional
practices of RISPERDAL, subject to approval by the U.S. District Court. The
Company added that the agreement resolves allegations related to the sales and
marketing of INVEGA, NATRECOR by Scios, Inc., as well as allegations related
to Janssen's interactions with Omnicare, Inc. According to Johnson & Johnson,
under the criminal resolution, Janssen will pay $400 million and plead guilty
to a one-count misdemeanor misbranding charge, while Janssen and Scios, will
together pay c.$1.6 billion to settle three pending civil False Claims Act
cases in federal district courts related to RISPERDAL and INVEGA, NATRECOR,
and Omnicare. The Full Research Report on Johnson & Johnson - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

Elan Corporation, plc (ADR) Research Report

On November 4, 2013, Elan Corporation plc's (ADR) (Elan) stock rose 0.29%,
ending the day at $17.05. Over the previous three trading sessions, shares of
Elan gained 6.63%, outperforming the S&P 500, which gained 0.26% during the
same period. The Full Research Report on Elan Corporation, plc (ADR) -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e996_ELN]

Tenet Healthcare Corp. Research Report

On November 4, 2013, Tenet Healthcare Corp. (Tenet) reported its Q3 2013
financial results. The Company's net operating revenues increased 8.4% YoY to
$2.4 billion during the quarter. Net income attributable to Tenet was $28
million or $0.27 per diluted share in Q3 2013, compared to net income
attributable to Tenet of $40 or $0.37 per diluted share in Q3 2012. Commenting
on the results, Trevor Fetter, President and CEO, said, "We delivered strong
growth in outpatient visits, emergency department volumes, and total surgeries
in the quarter, all of which are areas of strategic focus. In addition, our
Conifer services business continues to thrive, reporting a 50 percent increase
in EBITDA compared to last year's third quarter. Conifer recorded revenues of
$225 million, an increase of 84 percent. On October 1, we completed our
acquisition of Vanguard Health Systems, which further strengthens our
competitive position for future growth. The integration of Vanguard's
operations is proceeding smoothly and we are excited about the additional
strengths this acquisition brings to our Company." The Full Research Report on
Tenet Healthcare Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1d25_THC]

Opko Health Inc. Research Report

On November 4, 2013, Opko Health Inc. (Opko) announced that it has commenced a
pivotal, multi-center clinical validation study for the Company's proprietary
4Kscore test for the prediction of prostate cancer prior to prostate biopsy.
According to the Company, the OPKO multi-center study is expected to produce
data to support the launch of the 4Kscore test as a laboratory developed test
through the Company's CLIA laboratory in Nashville, Tennessee. Opko said that
it has begun enrolling patients at the first of 13 sites across the United
States and is planning to enroll more than 1,200 patients referred for a
biopsy over the course of the next few months. Davis Okrongly, Ph.D.,
President of OPKO Diagnostics, said, "Our clinical study with over 15 of the
leading and largest urology centers across the United States is the last step
before our commercial launch of the 4Kscore™ in the first quarter of 2014. The
data we generate in this clinical study will not only be used for the required
CLIA validation, but will also provide important data for securing 4Kscore™
reimbursement." The Full Research Report on Opko Health Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/cd43_OPK]

Keryx Biopharmaceuticals Research Report 

On November 4, 2013, Keryx Biopharmaceuticals (Keryx Biopharmaceuticals)
reported its Q3 2013 financial results. Net loss was $15.7 million or $0.19
per diluted share in Q3 2013, compared to net loss of $5.5 million or $0.08
per diluted share in Q3 2012. Ron Bentsur, CEO of Keryx Biopharmaceuticals,
said, "The last few months have been very exciting for the Company. We
submitted the Zerenex NDA, which filing has now been accepted by the FDA for
review, and has been assigned a PDUFA goal date of June 7, 2014. Additionally,
we have been actively building our commercial infrastructure with seasoned
professionals in the dialysis and chronic kidney disease therapeutic areas to
support the anticipated launch in mid-2014." The Full Research Report on Keryx
Biopharmaceuticals - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/27d2_KERX]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)